Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyUCare Adzynma Coverage Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentUCarePolicy 327

    Hematology - Adzynma Utilization Management Medical Policy

    Customize your policy alerts

    Sign up for UCare Policy 327 alerts

    Get alerted when Policy 327 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-benefit coverage of Adzynma for UCare members with congenital thrombotic thrombocytopenic purpura across pediatric and adult populations and all UCare plans.

    Policy Summary
    PayerUCare
    PolicyHematology - Adzynma Utilization Management Medical Policy
    Policy CodePolicy 327
    Change TypeClarification
    Effective DateMar 15, 2024
    Last ReviewSep 15, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization under the medical benefit and document that the patient meets the policy criteria and dosing requirements.
    SourceLink
    POLICY UPDATE CHANGES

    The criterion requiring a pathogenic variant in the ADAMTS13 gene was revised by removing the phrase "or a mutation," and the related note was revised accordingly.

    1 yearInitial authorization
    <10%Baseline ADAMTS13
    40 IU/kgRoutine prophylaxis
    135 IU/kgOn-demand maximum
    All UCare PlansCoverage scope

    Recommended Authorization Criteria

    Adzynma is not recommended for circumstances that are not listed in the Recommended Authorization Criteria. The criteria may be updated as new published data become available.

    Dosing and Laboratory Requirements

    Baseline ADAMTS13 activity
    Required activity<10% (<10 IU/dL)
    Routine prophylaxis dose
    Maximum dose and frequencyUp to 40 IU/kg by intravenous infusion once weekly
    On-demand therapy dose
    Maximum weekly dose
    Policy Summary
    PayerUCare
    PolicyHematology - Adzynma Utilization Management Medical Policy
    Policy CodePolicy 327
    Change TypeClarification
    Effective DateMar 15, 2024
    Last ReviewSep 15, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization under the medical benefit and document that the patient meets the policy criteria and dosing requirements.
    SourceLink
    On This Page
    Recommended Authorization CriteriaDosing and Laboratory RequirementsAuthorization and Documentation RequirementsClinical BackgroundPolicy Definitions

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Up to 135 IU/kg by intravenous infusion per week as needed for treatment of acute event(s)

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is recommended for medical-benefit coverage of Adzynma. Approval is recommended for 1 year when the patient meets the applicable Recommended Authorization Criteria and dosing requirements for congenital thrombotic thrombocytopenic purpura.

    Note

    Hematology Specialist Involvement

    Adzynma must be prescribed by or in consultation with a physician who specializes in the condition being treated. For congenital thrombotic thrombocytopenic purpura, the prescriber must be or consult with a hematologist.

    Documentation Required

    Supporting Clinical Documentation

    Submit patient-specific documentation supporting the authorization criteria. Documentation must include patient-specific identifying information and may include chart notes, laboratory data, genetic test results, and other relevant clinical information.

    Documentation Required

    Congenital TTP Diagnostic Evidence

    For congenital thrombotic thrombocytopenic purpura, document all of the following: baseline ADAMTS13 activity below 10% (below 10 IU/dL) before any treatment; absence of anti-ADAMTS13 autoantibodies by diagnostic testing; and a pathogenic variant in the ADAMTS13 gene. Pathogenic variants are usually homozygous or compound heterozygous.

    • Baseline means testing performed before Adzynma or any plasma-based therapy.
    • Documentation is required for ADAMTS13 activity, anti-ADAMTS13 autoantibody testing, and the pathogenic ADAMTS13 variant.
    Denial Risk

    Use Outside Listed Criteria

    Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria may be updated as new published data become available.

    Denial Risk

    Dosing Outside Policy Limits

    Requests for doses outside the established dosing limits in this policy will be reviewed case by case by a clinician, such as a Medical Director or Pharmacist.

    • Routine prophylaxis: up to 40 IU/kg by intravenous infusion once weekly.
    • On-demand therapy: up to 135 IU/kg by intravenous infusion per week as needed for acute events; although administered daily until 2 days after the event resolves, the total weekly dose must not exceed 135 IU/kg.

    Clinical Background

    Congenital thrombotic thrombocytopenic purpura (TTP) is a very rare inherited disorder caused by severe deficiency of the ADAMTS13 enzyme, typically resulting from pathogenic variants in the ADAMTS13 gene. The deficiency leads to platelet-rich microthrombi in small blood vessels, which may cause bleeding episodes, stroke, organ injury, or death. Adzynma provides recombinant ADAMTS13 enzyme replacement for prophylaxis or treatment of acute events in adults and pediatric patients.

    Policy Definitions

    Congenital thrombotic thrombocytopenic purpura
    ConditionA very rare inherited blood-clotting disorder caused by severe hereditary ADAMTS13 deficiency, generally less than 10% of normal activity.
    Underlying causeA mutation in the ADAMTS13 gene causes severe deficiency of the ADAMTS13 enzyme, which regulates blood clotting.
    Clinical effectThe deficiency causes blood clots to form in small blood vessels throughout the body.
    Baseline ADAMTS13 activity
    MeaningADAMTS13 activity measured before any treatment is received.
    Treatment excludedThis measurement must be obtained before treatment with Adzynma or plasma-based therapies.
    Required thresholdActivity below 10% (<10 IU/dL).
    On-demand therapy
    AdministrationGiven as a daily dose until 2 days after the acute event resolves.
    Weekly limitThe total weekly dose must not exceed 135 IU/kg.
    PurposeUsed as needed for the treatment of acute event(s).